Information:
Fel:
ID
19643
Beskrivning
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00719173
Länk
https://clinicaltrials.gov/show/NCT00719173
Nyckelord
Versioner (1)
- 2017-01-18 2017-01-18 -
Uppladdad den
18 januari 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT00719173
Eligibility Breast Cancer NCT00719173
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00719173
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Breast Carcinoma
Item
diagnosis of breast cancer
boolean
C0678222 (UMLS CUI [1])
Cyclophosphamide Intravenous infusion Planned
Item
planning to receive cyclophosphamide 600 mg/m²-1,000 mg/m² iv infusion
boolean
C0010583 (UMLS CUI [1,1])
C0021440 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C0021440 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
Cyclophosphamide Dose unchanged
Item
no cyclophosphamide dose change between courses 1 and 2
boolean
C0010583 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0442739 (UMLS CUI [1,3])
C0178602 (UMLS CUI [1,2])
C0442739 (UMLS CUI [1,3])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Life Expectancy
Item
life expectancy ≥ 2 months
boolean
C0023671 (UMLS CUI [1])
Absolute neutrophil count
Item
anc ≥ 1,500/μl
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count ≥ 100 x 10^9/l
boolean
C0032181 (UMLS CUI [1])
Hemoglobin measurement
Item
hemoglobin ≥ 9.0 g/dl
boolean
C0518015 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine ≤ 1.5 mg/dl
boolean
C0201976 (UMLS CUI [1])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
ast/alt ≤ 2 times upper limit of normal
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0201836 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
not pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Medical contraindication aprepitant
Item
no contraindication to aprepitant
boolean
C1301624 (UMLS CUI [1,1])
C1176306 (UMLS CUI [1,2])
C1176306 (UMLS CUI [1,2])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
disease characteristic
Item
see disease characteristics
boolean
C0599878 (UMLS CUI [1])
Cytochrome P-450 CYP3A4 Substrate | Cytochrome P450 3A4 Inhibitor | Cytochrome P450 3A4 Inducer | Dexamethasone | Antiemetics Standard therapy
Item
no concurrent medications that are cyp3a4 substrates, inhibitors, and/or inducers, with the exception of the dexamethasone contained as part of the standard antiemetic regimen
boolean
C3714798 (UMLS CUI [1,1])
C3891814 (UMLS CUI [1,2])
C3830624 (UMLS CUI [2])
C3830625 (UMLS CUI [3])
C0011777 (UMLS CUI [4])
C0003297 (UMLS CUI [5,1])
C2936643 (UMLS CUI [5,2])
C3891814 (UMLS CUI [1,2])
C3830624 (UMLS CUI [2])
C3830625 (UMLS CUI [3])
C0011777 (UMLS CUI [4])
C0003297 (UMLS CUI [5,1])
C2936643 (UMLS CUI [5,2])